Chey WD

No ORCID on file · 4 papers in corpus · active 2018-2022

Condition tags

  • irritable_bowel_syndrome 2
2022
Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.
Neurogastroenterology and motility ·doi:10.1111/nmo.14448

BackgroundPreclinical and clinical studies suggest that β3 -adrenergic receptor activation may be a novel target for treating abdominal pain and gastrointestinal motility dysfunction in patients with irritable bowel syndrome (IBS). This pro…

2020
Presentation and Characteristics of Abdominal Pain Vary by Irritable Bowel Syndrome Subtype: Results of a Nationwide Population-Based Study.
The American journal of gastroenterology ·doi:10.14309/ajg.0000000000000502

IntroductionAbdominal pain is a cardinal feature of irritable bowel syndrome (IBS); however, differences in abdominal pain among IBS subtypes remain unknown. We aimed to characterize abdominal pain symptoms among established IBS subtypes us…

2020
Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms.
Gastroenterology ·doi:10.1053/j.gastro.2019.12.014

Background & aimsThere are few data on the prevalence of gastroesophageal reflux disease (GERD) in the United States. We performed a population-based study to determine the prevalence of GERD symptoms and persistent GERD symptoms despite us…

2018
Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans.
The American journal of gastroenterology ·doi:10.1038/s41395-018-0256-8

ObjectivesDigestive diseases account for >100 million ambulatory care visits annually in the U.S. Yet, comparatively less is known about the true burden of gastrointestinal (GI) symptoms in the general U.S.PopulationThe aim of this study wa…